GPER1-mediated immunomodulation and neuroprotection in the myenteric plexus of a mouse model of Parkinson's disease

Neurobiology of Disease

Volumn 82, Issue , 2015, Pages 99-113

  Côté, Mélissa ^a,b   Bourque, Mélanie ^a,b   Poirier, Andrée Anne ^a,b   Aubé, Benoit ^a   Morissette, Marc ^a   Di Paolo, Thérèse ^a,b   Soulet, Denis ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

17 estradiol; GPER1; Ileum; Immunophenotype; Inflammation; Innate immune response; Intestine; MPTP; Myenteric plexus; Neuroprotection

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CD14 ANTIGEN; CD16 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; ESTRADIOL; ESTROGEN RECEPTOR ANTAGONIST; G PROTEIN COUPLED ESTROGEN RECEPTOR 1 AGONIST G1; G PROTEIN COUPLED ESTROGEN RECEPTOR 1 ANTAGONIST G15; HORMONE RECEPTOR STIMULATING AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; 1,3 BENZODIOXOLE DERIVATIVE; 4-(6-BROMO-1,3-BENZODIOXOL-5-YL)-3A,4,5,9B-3H-CYCLOPENTA(C)QUINOLINE; ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GPR30 PROTEIN, MOUSE; NEUROPROTECTIVE AGENT; NOS2 PROTEIN, MOUSE; QUINOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG ANTAGONISM; DRUG POTENCY; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOMODULATION; IMMUNOPHENOTYPING; IN VITRO STUDY; INNATE IMMUNITY; MACROPHAGE; MACROPHAGE MIGRATION; MALE; MONOCYTE; MOUSE; MYENTERIC PLEXUS; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; PARKINSONIAN DISORDERS; PATHOLOGY;

ANIMALS; BENZODIOXOLES; DOPAMINERGIC NEURONS; ESTRADIOL; IMMUNOMODULATION; MICE; MYENTERIC PLEXUS; NEUROPROTECTION; NEUROPROTECTIVE AGENTS; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; PARKINSONIAN DISORDERS; QUINOLINES; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84931291958     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.05.017     Document Type: Article

References (56)

1. Abbott R.D., Petrovitch H., White L.R., Masaki K.H., Tanner C.M., Curb J.D., Grandinetti A., Blanchette P.L., Popper J.S., Ross G.W. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001, 57(3):456-462.
2. Anderson G., Noorian A.R., Taylor G., Anitha M., Bernhard D., Srinivasan S., Greene J.G. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease. Exp. Neurol. 2007, 207(1):4-12.
3. Annerino D.M., Arshad S., Taylor G.M., Adler C.H., Beach T.G., Greene J.G. Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol. 2012, 124(5):665-680.
4. Armstrong B.D., Abad C., Chhith S., Cheung-Lau G., Hajji O.E., Nobuta H., Waschek J.A. Impaired nerve regeneration and enhanced neuroinflammatory response in mice lacking pituitary adenylyl cyclase activating peptide. Neuroscience 2008, 151(1):63-73.
5. Bologa C.G., Revankar C.M., Young S.M., Edwards B.S., Arterburn J.B., Kiselyov A.S., Parker M.A., Tkachenko S.E., Savchuck N.P., Sklar L.A., Oprea T.I., Prossnitz E.R. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol. 2006, 2(4):207-212.
6. Bourque M., Dluzen D.E., Di Paolo T. Neuroprotective actions of sex steroids in Parkinson's disease. Front. Neuroendocrinol. 2009, 30(2):142-157.
7. Bourque M., Morissette M., Cote M., Soulet D., Di Paolo T. Implication of GPER1 in neuroprotection in a mouse model of Parkinson's disease. Neurobiol. Aging 2013, 34(3):887-901.
8. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24(2):197-211.
9. Callier S., Morissette M., Grandbois M., Di Paolo T. Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice. Synapse 2000, 37(4):245-251.
10. Cote M., Drouin-Ouellet J., Cicchetti F., Soulet D. The critical role of the MyD88-dependent pathway in non-CNS MPTP-mediated toxicity. Brain Behav. Immun. 2011, 25(6):1143-1152.
11. Cote M., Poirier A.A., Aube B., Jobin C., Lacroix S., Soulet D. Partial depletion of the proinflammatory monocyte population is neuroprotective in the myenteric plexus but not in the basal ganglia in a MPTP mouse model of Parkinson's disease. Brain Behav. Immun. 2015, 46:154-167.
12. Delgado M., Ganea D. Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J. 2003, 17(13):1922-1924.
13. Dennis M.K., Burai R., Ramesh C., Petrie W.K., Alcon S.N., Nayak T.K., Bologa C.G., Leitao A., Brailoiu E., Deliu E., Dun N.J., Sklar L.A., Hathaway H.J., Arterburn J.B., Oprea T.I., Prossnitz E.R. In vivo effects of a GPR30 antagonist. Nat. Chem. Biol. 2009, 5(6):421-427.
14. Devos D., Lebouvier T., Lardeux B., Biraud M., Rouaud T., Pouclet H., Coron E., Bruley des Varannes S., Naveilhan P., Nguyen J.M., Neunlist M., Derkinderen P. Colonic inflammation in Parkinson's disease. Neurobiol. Dis. 2013, 50:42-48.
15. Drolet R.E., Cannon J.R., Montero L., Greenamyre J.T. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol. Dis. 2009, 36(1):96-102.
16. Forsyth C.B., Shannon K.M., Kordower J.H., Voigt R.M., Shaikh M., Jaglin J.A., Estes J.D., Dodiya H.B., Keshavarzian A. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS ONE 2011, 6(12). (e28032).
17. Greene J.G., Noorian A.R., Srinivasan S. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease. Exp. Neurol. 2009, 218(1):154-161.
18. Hawkes C.H., Del Tredici K., Braak H. Parkinson's disease: the dual hit theory revisited. Ann. N. Y. Acad. Sci. 2009, 1170:615-622.
19. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8(4):382-397.
20. Holst M.C., Powley T.L. Cuprolinic blue (quinolinic phthalocyanine) counterstaining of enteric neurons for peroxidase immunocytochemistry. J. Neurosci. Methods 1995, 62(1-2):121-127.
21. Kelly L.P., Carvey P.M., Keshavarzian A., Shannon K.M., Shaikh M., Bakay R.A., Kordower J.H. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov. Disord. 2014, 29(8):999-1009.
22. Kuo Y.M., Li Z., Jiao Y., Gaborit N., Pani A.K., Orrison B.M., Bruneau B.G., Giasson B.I., Smeyne R.J., Gershon M.D., Nussbaum R.L. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum. Mol. Genet. 2010, 19(9):1633-1650.
23. Lebouvier T., Chaumette T., Damier P., Coron E., Touchefeu Y., Vrignaud S., Naveilhan P., Galmiche J.P., Bruley des Varannes S., Derkinderen P., Neunlist M. Pathological lesions in colonic biopsies during Parkinson's disease. Gut 2008, 57(12):1741-1743.
24. Lebouvier T., Chaumette T., Paillusson S., Duyckaerts C., Bruley des Varannes S., Neunlist M., Derkinderen P. The second brain and Parkinson's disease. Eur. J. Neurosci. 2009, 30(5):735-741.
25. Lebouvier T., Coron E., Chaumette T., Paillusson S., Bruley des Varannes S., Neunlist M., Derkinderen P. Routine colonic biopsies as a new tool to study the enteric nervous system in living patients. Neurogastroenterol. Motil. 2010, 22(1):e11-e14.
26. Lebouvier T., Neunlist M., Bruley des Varannes S., Coron E., Drouard A., N'Guyen J.M., Chaumette T., Tasselli M., Paillusson S., Flamand M., Galmiche J.P., Damier P., Derkinderen P. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS ONE 2010, 5(9). (e12728).
27. Li Z.S., Schmauss C., Cuenca A., Ratcliffe E., Gershon M.D. Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice. J. Neurosci. 2006, 26(10):2798-2807.
28. Liu B., Dluzen D.E. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease. Clin. Exp. Pharmacol. Physiol. 2007, 34(7):555-565.
29. McGeer P.L., McGeer E.G. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat. Disord. 2004, 10(Suppl. 1):S3-S7.
30. Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. 1996, 211(1):13-16.
31. Morale M.C., Serra P.A., L'Episcopo F., Tirolo C., Caniglia S., Testa N., Gennuso F., Giaquinta G., Rocchitta G., Desole M.S., Miele E., Marchetti B. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience 2006, 138(3):869-878.
32. Nagatsu T., Mogi M., Ichinose H., Togari A. Cytokines in Parkinson's disease. J. Neural Transm. Suppl. 2000, 58:143-151.
33. Natale G., Kastsiushenka O., Fulceri F., Ruggieri S., Paparelli A., Fornai F. MPTP-induced parkinsonism extends to a subclass of TH-positive neurons in the gut. Brain Res. 2010, 1355:195-206.
34. Natale G., Pasquali L., Ruggieri S., Paparelli A., Fornai F. Parkinson's disease and the gut: a well known clinical association in need of an effective cure and explanation. Neurogastroenterol. Motil. 2008, 20(7):741-749.
35. Noorian A.R., Rha J., Annerino D.M., Bernhard D., Taylor G.M., Greene J.G. Alpha-synuclein transgenic mice display age-related slowing of gastrointestinal motility associated with transgene expression in the vagal system. Neurobiol. Dis. 2012, 48(1):9-19.
36. Ohtaki H., Nakamachi T., Dohi K., Aizawa Y., Takaki A., Hodoyama K., Yofu S., Hashimoto H., Shintani N., Baba A., Kopf M., Iwakura Y., Matsuda K., Arimura A., Shioda S. Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(19):7488-7493.
37. Otto C., Fuchs I., Altmann H., Klewer M., Schwarz G., Bohlmann R., Nguyen D., Zorn L., Vonk R., Prelle K., Osterman T., Malmstrom C., Fritzemeier K.H. In vivo characterization of estrogen receptor modulators with reduced genomic versus nongenomic activity in vitro. J. Steroid Biochem. Mol. Biol. 2008, 111(1-2):95-100.
38. Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2003, 2(2):107-116.
39. Phillips R.J., Walter G.C., Wilder S.L., Baronowsky E.A., Powley T.L. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease?. Neuroscience 2008, 153(3):733-750.
40. Poewe W. The natural history of Parkinson's disease. J. Neurol. 2006, 253(Suppl. 7):VII2-VII6.
41. Reichmann H. Clinical criteria for the diagnosis of Parkinson's disease. Neurodegener. Dis. 2010, 7(5):284-290.
42. Savica R., Carlin J.M., Grossardt B.R., Bower J.H., Ahlskog J.E., Maraganore D.M., Bharucha A.E., Rocca W.A. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 2009, 73(21):1752-1758.
43. Savica R., Rocca W.A., Ahlskog J.E. When does Parkinson disease start?. Arch. Neurol. 2010, 67(7):798-801.
44. Schapira A.H., Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal?. Ann. Neurol. 2006, 59(3):559-562.
45. Shannon K.M., Keshavarzian A., Mutlu E., Dodiya H.B., Daian D., Jaglin J.A., Kordower J.H. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov. Disord. 2012, 27(6):709-715.
46. Simard M., Boucher E., Provost P.R., Tremblay Y. Minimization of PCR efficiency differences between standards and samples through dilution of PCR amplicons in reverse transcription buffer. Anal. Biochem. 2007, 362(1):142-144.
47. Singaram C., Ashraf W., Gaumnitz E.A., Torbey C., Sengupta A., Pfeiffer R., Quigley E.M. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995, 346(8979):861-864.
48. Straub R.H. The complex role of estrogens in inflammation. Endocr. Rev. 2007, 28(5):521-574.
49. Tan Y.V., Abad C., Lopez R., Dong H., Liu S., Lee A., Gomariz R.P., Leceta J., Waschek J.A. Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(6):2012-2017.
50. Taylor H.S., Manson J.E. Update in hormone therapy use in menopause. J. Clin. Endocrinol. Metab. 2011, 96(2):255-264.
51. Tripanichkul W., Sripanichkulchai K., Finkelstein D.I. Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication. Brain Res. 2006, 1084(1):28-37.
52. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3(7). (RESEARCH0034).
53. Wakabayashi K., Takahashi H., Ohama E., Ikuta F. Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol. 1990, 79(6):581-583.
54. Wang L., Fleming S.M., Chesselet M.F., Tache Y. Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. Neuroreport 2008, 19(8):873-876.
55. Wang L., Magen I., Yuan P.Q., Subramaniam S.R., Richter F., Chesselet M.F., Tache Y. Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation. Neurogastroenterol. Motil. 2012, 24(9):e425-e436.
56. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J. Leukoc. Biol. 2007, 81(3):584-592.